Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

Core Insights - Esperion is hosting a virtual key opinion leader (KOL) event to discuss the challenges of statin intolerance and its impact on patient outcomes, emphasizing the company's commitment to addressing this unmet need [1][2] Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for patients at risk of cardiovascular disease, specifically targeting elevated low-density lipoprotein cholesterol (LDL-C) [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for this patient population, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [3] Industry Context - Cardiovascular disease is the leading cause of morbidity and mortality globally, with nearly 20% of patients discontinuing statin therapy within the first year, often without transitioning to alternative treatments [2] - The urgent need for innovative solutions in cardiovascular care is highlighted, as patients who discontinue statin therapy remain vulnerable to serious cardiovascular events [2]